ストックスクリーナーアプリを入手
8.97
1.36%
0.12
前日終値:
$8.85
開ける：
$8.81
24時間の取引高:
18,922
Relative Volume:
0.19
時価総額：
$47.49M
収益：
$7.97M
当期純損益:
$-75.74M
株価収益率:
-0.3694
EPS:
-24.2853
ネットキャッシュフロー:
$-85.33M
1週間 パフォーマンス:
+18.26%
1か月 パフォーマンス:
+3.82%
6か月 パフォーマンス:
-51.85%
1年 パフォーマンス:
-34.76%
1日の値動き範囲:
$8.39
$8.90
1週間の範囲:
$7.42
$9.00
52週間の値動き範囲:
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
名前
Aligos Therapeutics Inc
セクター
電話
(800) 466-6059
住所
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
ALGS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
8.875 | 60.96M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.19 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
601.71 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.30 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
665.82 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
311.21 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-19 | 開始されました | H.C. Wainwright | Buy |
| 2023-01-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-01-06 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-01-06 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-09 | 開始されました | SVB Leerink | Outperform |
| 2021-05-17 | 再開されました | Piper Sandler | Overweight |
| 2020-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 開始されました | JP Morgan | Overweight |
| 2020-11-10 | 開始されました | Jefferies | Buy |
| 2020-11-10 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Aligos Therapeutics Inc (ALGS) 最新ニュース
Aligos Therapeutics appoints Ramon Polo as head of global regulatory affairs - TipRanks
Aligos Therapeutics appoints Ramón Polo as head of global regulatory - Investing.com
Aligos Therapeutics Appoints Ramón Polo as Senior VP, Head of Global Regulatory Affairs - Quiver Quantitative
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs - The Globe and Mail
Former J&J COVID-19 Vaccine Regulatory Leader Joins Aligos Therapeutics as Global Regulatory Head - Stock Titan
Is Aligos Therapeutics Inc. forming a bottoming baseQuarterly Market Summary & Technical Pattern Recognition Alerts - Newser
Aligos Therapeutics Inc. stock outlook for YEARJuly 2025 Spike Watch & Accurate Intraday Trade Tips - Newser
Sector ETF performance correlation with Aligos Therapeutics Inc.Weekly Risk Summary & Community Verified Trade Signals - Newser
Will Aligos Therapeutics Inc. continue its uptrendWeekly Trend Summary & Fast Gaining Stock Strategy Reports - Newser
Is Aligos Therapeutics Inc. meeting your algorithmic filter criteria2025 Short Interest & Advanced Swing Trade Entry Plans - Newser
What data driven models say about Aligos Therapeutics Inc.’s future2025 Trading Recap & Capital Efficiency Focused Ideas - Newser
Aligos Therapeutics Inc. recovery potential after sell offJuly 2025 Trade Ideas & Risk Adjusted Buy/Sell Alerts - Newser
Can volume confirm reversal in Aligos Therapeutics Inc.Bond Market & Safe Capital Growth Tips - Newser
Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know - Zacks Investment Research
Will Aligos Therapeutics Inc. stock go up soonJuly 2025 Catalysts & Community Trade Idea Sharing Platform - Newser
Can you recover from losses in Aligos Therapeutics Inc.July 2025 Breakouts & Reliable Price Breakout Alerts - Newser
Aligos Therapeutics Inc. stock momentum explainedJuly 2025 Spike Watch & Safe Entry Point Identification - Newser
Will Aligos Therapeutics Inc. stock recover after recent drop2025 Biggest Moves & AI Driven Stock Reports - Newser
Real time breakdown of Aligos Therapeutics Inc. stock performanceEarnings Risk Report & AI Forecast Swing Trade Picks - Newser
Aligos Therapeutics stock gets Buy rating from H.C. Wainwright on HBV drug potential - Investing.com India
H.C. Wainwright Assumes Coverage of Aligos Therapeutics with Buy Rating - AInvest
Aligos Therapeutics assumed with a Buy at H.C. Wainwright - TipRanks
Aligos Therapeutics receives Buy rating and $50 price target from HC Wainwright & Co. - AInvest
Does Aligos Therapeutics Inc. show high probability of reboundEarnings Overview Report & Low Risk High Win Rate Picks - Newser
Smart tools for monitoring Aligos Therapeutics Inc.’s price actionJuly 2025 Summary & Proven Capital Preservation Tips - Newser
Will Aligos Therapeutics Inc. price bounce be sustainableAnalyst Upgrade & Advanced Swing Trade Entry Plans - Newser
How Efficient Is Aligos Therapeutics Inc. at Controlling Operating CostsJuly 2025 Big Picture & Real-Time Chart Breakout Alerts - Newser
Ranking Aligos Therapeutics Inc. among high performing stocks via tools - Newser
How to monitor Aligos Therapeutics Inc. with trend dashboardsWeekly Loss Report & Weekly Watchlist of Top Performers - Newser
Custom watchlist performance reports with Aligos Therapeutics Inc.July 2025 Sector Moves & Community Consensus Trade Alerts - Newser
Volatility clustering patterns for Aligos Therapeutics Inc.Weekly Profit Analysis & Fast Entry Momentum Alerts - Newser
News impact scoring models applied to Aligos Therapeutics Inc.2025 Institutional Moves & Daily Chart Pattern Signals - Newser
Is There Enough Volume to Lift Aligos Therapeutics Inc.Portfolio Update Report & Free Community Supported Trade Ideas - newsyoung.net
What is the dividend yield of Aligos Therapeutics Inc.2025 Trading Recap & Daily Risk Controlled Trade Plans - thegnnews.com
Is Aligos Therapeutics Inc. stock undervalued right nowWeekly Market Summary & AI Driven Price Forecasts - thegnnews.com
Using flow based indicators on Aligos Therapeutics Inc.Trade Volume Report & AI Driven Stock Reports - Newser
Using Bollinger Bands to evaluate Aligos Therapeutics Inc.July 2025 Opening Moves & Real-Time Buy Signal Alerts - Newser
Aligos Therapeutics Inc (ALGS) 財務データ
収益
当期純利益
現金流量
EPS
1.13%
0.26%
大文字化:
|
ボリューム (24 時間):